Noteworthy Stocks to Watch for: ItauUnibanco Holding S.A. (NYSE:ITUB), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

u.s stocks

ItauUnibanco Holding S.A. (NYSE:ITUB)

The company announced its last quarter financial performance results on 11/01/2016. ItauUnibanco Holding S.A. (NYSE:ITUB) belongs to Finance sector that declined -1.24% in value when last trading session closed at $11.92. The company has a market capitalization of $73.45 Billion. The company’s stock has a Return on Assets (ROA) of 1.7 percent, a Return on Equity (ROE) of 19.2 percent and Return on Investment (ROI) of 8 percent. The company reached its 52-Week high of $12.22 on Jan 27, 2017 and 52-Week low of $5.24 on Feb 2, 2016.

Earnings per share (ttm) for ItauUnibanco Holding S.A. (NYSE:ITUB) according to Finviz Data is $1.05.

The growth estimate for ItauUnibanco Holding S.A. (NYSE:ITUB) for the current quarter is 17.4 percent. The projected growth estimate for the next quarter is 18.2 percent. The company’s stock has grown by -1.68 percent in the past 5 years. For the next 5 years, the company is expected to grow by 6.68 percent.

This company was Upgrade by Goldman on 20-Jul-16  to Neutral.

The 15 analysts offering 12-month price forecasts for ItauUnibanco Holding SA have a median target of 11.38, with a high estimate of 14.18 and a low estimate of 7.79. The median estimate represents a -4.57% decrease from the last price of 11.92.

Financial History:

Following Earnings result, share price were UP 4 times out of last 6 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 83% percent of times. It has met expectations  1 times and missed earnings  1 times.

The consensus recommendation for ItauUnibanco Holding S.A. (NYSE:ITUB) is 2.6. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.6. In comparison, the consensus recommendation 60 days ago was at 2.33, and 90 days ago was at 2.33 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects ItauUnibanco Holding S.A. to have earnings per share of $0.27.

Revenue is expected to range from 8.25 Billion to 8.55 Billion with an average of 8.4 Billion.

Company Profile:

BANCO ITAU -ADR’s main goal is to focus on an equilibrium between growth and profitability, aimed at always generating value for the stockholder in the long run.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA):

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Medical sector closed its last session with a loss of -0.13 percent and closed its previous trading session at $23.65. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-0.18. The company has the Market capitalization of $4.59 Billion. The company’s stock has a Return on Assets (ROA) of -5.4 percent, a Return on Equity (ROE) of 37.1 percent and Return on Investment (ROI) of -62.9 percent. The company reached its 52-Week high of $23.81 on Jan 9, 2017 and 52-Week low of $4.37 on Feb 11, 2016.

This company was Downgrade by SunTrust on 11-Jan-17 to Hold.

The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 24.00 and a low estimate of 14.00. The median estimate represents a +1.48% increase from the last price of 23.65.

Financial History:

Following Earnings result, share price were DOWN 15 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  0 times and missed earnings  5  times.

The consensus recommendation for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is 2.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.33. In comparison, the consensus recommendation 60 days ago was at 2.33, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Ariad Pharmaceuticals Inc. to have earnings per share of $-0.18.

Revenue is expected to range from 42.5 Million to 47.57 Million with an average of 44.15 Million.

Company Profile:

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology.  The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology.  The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.